AVBP
HealthcareArriVent BioPharma, Inc. Common Stock · Biotechnology · $1B
What is ArriVent BioPharma, Inc. Common Stock?
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer, particularly those with non-small-cell lung cancer and other solid tumors.
The company identifies, develops, and aims to commercialize medicines addressing unmet needs in oncology. Its primary focus is on epidermal growth factor receptor mutant-selective therapies for non-small-cell lung cancer. ArriVent generates no product revenue at this stage — it is pre-commercial and funds operations through capital raises while advancing its pipeline through clinical trials.
ArriVent BioPharma was incorporated in 2021 and is headquartered in Newtown Square, Pennsylvania.
- Furmonertinib — an EGFR mutant-selective tyrosine kinase inhibitor in Phase 3 trials for NSCLC
- ARR-002 — an early-stage pipeline candidate
- Strategic collaboration with Aarvik Therapeutics Inc.
- Targeted oncology research platform focused on solid tumors
Is AVBP a Good Stock to Buy?
UQS Score rates AVBP as Poor overall, reflecting the early-stage nature of its pipeline and the significant uncertainties typical of clinical-stage biotechs.
The Risk pillar stands out as the relative bright spot in AVBP's profile, suggesting the company carries a manageable near-term financial risk profile compared to some peers at a similar development stage.
Quality, Moat, Growth, and Valuation all register as weak or elevated concerns — consistent with a pre-revenue company where clinical outcomes remain the primary value driver.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AVBP pay dividends?
No — ArriVent BioPharma, Inc. Common Stock does not currently pay a dividend.
AVBP does not pay a dividend. As a clinical-stage company with no commercial revenue, capital is directed entirely toward advancing clinical trials and pipeline development. Income-focused investors should note that a dividend is unlikely until the company reaches commercialization — a milestone that remains contingent on trial outcomes.
When does AVBP report earnings?
ArriVent BioPharma reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports center on pipeline progress, cash runway, and operating expenses rather than sales or earnings growth. Investors typically focus on clinical trial updates and capital position disclosures.
For the most recent quarter's results and pipeline updates, visit ArriVent BioPharma's investor relations page.
AVBP Price History
+43.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ArriVent BioPharma, Inc. Common Stock?
Based on ArriVent BioPharma, Inc. Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AVBP Long-term Outlook
AVBP's fundamental outlook is shaped almost entirely by the clinical trajectory of Furmonertinib. The Growth pillar registers as Weak, reflecting the absence of commercial revenue and the binary nature of late-stage trial readouts. The Valuation pillar is Elevated, meaning the market is pricing in a degree of success that the current pipeline stage has yet to validate. Execution on Phase 3 milestones and potential regulatory submissions represent the clearest path to a re-rating.
Growth drivers
- Phase 3 clinical progress for Furmonertinib in NSCLC
- Potential regulatory submissions and partnership opportunities in targeted oncology
- Expansion of the pipeline through the Aarvik Therapeutics collaboration
Key risks
- Clinical trial failure or delays — the primary binary risk for any pre-commercial biotech
- Elevated valuation relative to the current development stage leaves limited margin for setbacks
- Ongoing capital needs and dilution risk as the company funds operations pre-revenue
AVBP vs Peers
AVBP operates in a competitive clinical-stage oncology landscape alongside several peers pursuing targeted cancer therapies.
MoonLake focuses on inflammatory diseases rather than oncology, giving it a distinct therapeutic focus compared to AVBP's cancer-centered pipeline.
Bicara develops bispecific antibody therapies targeting solid tumors, representing a different mechanistic approach to the same oncology patient population.
Inhibrx pursues a broader platform of protein engineering across multiple therapeutic areas, offering more pipeline diversification than AVBP's concentrated NSCLC focus.
Frequently Asked Questions
What does ArriVent BioPharma do?
ArriVent BioPharma is a clinical-stage oncology company developing targeted therapies for patients with non-small-cell lung cancer and other solid tumors. Its lead program, Furmonertinib, is an EGFR mutant-selective tyrosine kinase inhibitor currently in Phase 3 clinical trials. The company has no commercial products yet and is focused on advancing its pipeline toward potential regulatory approval.
Does AVBP pay dividends?
No, AVBP does not pay a dividend. The company is pre-revenue and allocates all available capital to clinical development. A dividend is not expected until the company achieves commercialization, which depends on successful trial outcomes and regulatory approvals.
When does AVBP report earnings?
ArriVent BioPharma reports on a quarterly cadence typical of US-listed companies. Because it is pre-commercial, reports focus on pipeline milestones and cash position rather than revenue. Check the company's investor relations page for the latest schedule and results.
Is AVBP a good stock to buy?
UQS Score rates AVBP as Poor overall, driven by Weak readings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The Risk pillar is the relative standout. Whether AVBP fits a portfolio depends on an investor's tolerance for clinical-stage binary risk. The full pillar breakdown is available to UQS Pro members.
Is AVBP overvalued?
The UQS Valuation pillar for AVBP is rated Elevated, suggesting the current market price reflects optimistic assumptions about clinical success that have not yet been validated by data. Pre-commercial biotechs often carry elevated valuations relative to fundamentals, with value contingent on trial outcomes.
How does AVBP compare to its competitors?
AVBP competes in the clinical-stage oncology space alongside companies like Bicara Therapeutics and Inhibrx Biosciences. Each pursues different mechanisms or therapeutic areas. AVBP's differentiation lies in its EGFR-selective approach to NSCLC, though it faces the same pre-revenue risks common to all clinical-stage peers.
What is AVBP's market cap bracket?
AVBP is classified as a small-cap stock. This is typical for clinical-stage biopharmaceutical companies that have not yet reached commercialization, where market capitalization reflects pipeline potential rather than current revenue or earnings.
Who founded ArriVent BioPharma?
ArriVent BioPharma was incorporated in 2021 and is headquartered in Newtown Square, Pennsylvania. For detailed founding history and leadership background, the company's investor relations and about pages provide publicly available information on its origins and management team.
Is AVBP a long-term quality investment?
As a long-term quality indicator, AVBP's UQS Score of Poor reflects meaningful structural challenges — no revenue, a Weak Moat, and an Elevated Valuation. Long-term quality typically requires durable competitive advantages and financial strength, neither of which a pre-commercial biotech can demonstrate until pipeline assets reach the market.
What is the main competitive advantage of ArriVent BioPharma?
ArriVent's potential competitive advantage centers on the selectivity profile of Furmonertinib as an EGFR mutant-targeted therapy for NSCLC — a large and underserved patient population. However, the UQS Moat pillar is currently rated Weak, reflecting that no durable commercial moat has been established ahead of regulatory approval.
Unlock Full AVBP Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics and trend data for ArriVent BioPharma
- ✓Compare AVBP side-by-side with clinical-stage oncology peers
- ✓Screen for higher-scoring small-cap biotech alternatives
- ✓Get the full analyst-style view available exclusively to Pro members
Pro Analysis
AVBP — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 13.5 | 0.0 | 11.0 | 0.0 | 71.4 | 0.0 | -0.2 |
| Apr 2, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 72.8 | 0.0 | — |
AVBP — Pillar Breakdown
Quality
— 0.0/100 (25%)ArriVent BioPharma, Inc. Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)ArriVent BioPharma, Inc. Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.4/100 (15%)ArriVent BioPharma, Inc. Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)ArriVent BioPharma, Inc. Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)ArriVent BioPharma, Inc. Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AVBP.
Score Composition
Financial Data
More Stock Analysis
How is the AVBP UQS Score Calculated?
The UQS (Unified Quality Score) for ArriVent BioPharma, Inc. Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ArriVent BioPharma, Inc. Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ArriVent BioPharma, Inc. Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.